Global developments in 2020
In 2020, the company’s primary focus has been in science relative to immunity and human genetics. This has been made possible through the application of highly sophisticated computer systems or deep artificial intelligence. Further, with an increase in the global number of studies in clinical oncology over the last few years, GSK’s performance reflected unparalleled success in the area of research and development with four assets of the company progressing into the phase II and III of the clinical study. What is more, approval for medicines for HIV treatment including antiretrovirals, influenza and respiratory disorders were also received. Clinical trials are research studies that involve people.Product portfolio
In the area of pharmaceuticals, GSK produces medications to combat several major diseases. The spectrum ranges from the increasing number of asthmatic and diabetic cases to infections, cancers and problems related to mental health. With regard to consumer health products and with the rise in prevalence of oral disorders, predominantly in India, GSK has established itself as one of the world’s leading sensitivity brands that has created a significant impact in the global, as well as Indian toothpaste segment. Some of the other leading and recognized products are Crocin, one India’s leading analgesics in the non-prescription category and Otrivin, a nasal decongestant.Vaccine market and COVID-19
GSK belongs to the leading global players in the vaccine market based on revenue and in 2019, the company generated a revenue of over 9.14 billion U.S. dollars through the sales of vaccines alone. The global vaccine market is projected to experience an exponential growth in the years to come, compounded with the recent global COVID-19 pandemic. The world’s leading vaccine companies are now in fierce competition with each other to develop the world’s first and most effective vaccine to combat this highly communicable and life-threatening virus known as the coronavirus. As of June 2022, GSK was ranked third among global companies with a total of ten COVID-drugs and vaccines in development.In April 2020, GSK joined forces with rival Sanofi in the COVID-19 vaccine development. While Sanofi developed the antigen, the adjuvant, which is the key component of the vaccine was developed by GSK to boost the immune response of the antigen. As of July 2021, Sanofi and GSK Plc received an approval from the Indian government for a late-stage clinical trial after early-stage results of the vaccine reported a robust immune response. The vaccine is a first of its kind being DNA-based as opposed to RNA-based vaccines. Further, India would also be host to the first foreign COVID-19 vaccine to be conducted within the country.
